Oral anticoagulants: A plausible new treatment for Alzheimer's disease?

Autor: Toribio-Fernandez R; Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain.; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain., Ceron C; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain., Tristão-Pereira C; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain., Fernandez-Nueda I; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain., Perez-Castillo A; Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.; Instituto de Investigaciones Biomédicas 'Alberto Sols' (CSIC-UAM), Madrid, Spain., Fernandez-Ferro J; Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain.; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.; Stroke Unit, Neurology Service, Hospital Universitario Rey Juan Carlos (HURJC), Madrid, Spain., Moro MA; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain., Ibañez B; Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain.; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.; CIBER de enfermedades cardiovasculares (CIBERCV), ISCIII, Madrid, Spain., Fuster V; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.; Icahn School of Medicine at Mount Sinai, New York, New York, USA., Cortes-Canteli M; Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain.; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.; Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Jazyk: angličtina
Zdroj: British journal of pharmacology [Br J Pharmacol] 2024 Mar; Vol. 181 (6), pp. 760-776. Date of Electronic Publication: 2023 Jan 31.
DOI: 10.1111/bph.16032
Abstrakt: Alzheimer's disease (AD) and cardiovascular disease (CVD) are strongly associated. Both are multifactorial disorders with long asymptomatic phases and similar risk factors. Indeed, CVD signatures such as cerebral microbleeds, micro-infarcts, atherosclerosis, cerebral amyloid angiopathy and a procoagulant state are highly associated with AD. However, AD and CVD co-development and the molecular mechanisms underlying such associations are not understood. Here, we review the evidence regarding the vascular component of AD and clinical studies using anticoagulants that specifically evaluated the development of AD and other dementias. Most studies reported a markedly decreased incidence of composite dementia in anticoagulated patients with atrial fibrillation, with the highest benefit for direct oral anticoagulants. However, sub-analyses by differential dementia diagnosis were scarce and inconclusive. We finally discuss whether anticoagulation could be a plausible preventive/therapeutic approach for AD and, if so, which would be the best drug and strategy to maximize clinical benefit and minimize potential risks. LINKED ARTICLES: This article is part of a themed issue From Alzheimer's Disease to Vascular Dementia: Different Roads Leading to Cognitive Decline. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v181.6/issuetoc.
(© 2023 British Pharmacological Society.)
Databáze: MEDLINE
Externí odkaz: